Cargando…

Erratum: Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC–IV ovarian cancer

Detalles Bibliográficos
Autores principales:	Tozzi, Roberto, Casarin, Jvan, Baysal, Ahmet, Valenti, Gaetano, Kilic, Yakup, Majd, Hooman Soleymani, Morotti, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658605/ https://www.ncbi.nlm.nih.gov/pubmed/31179650 http://dx.doi.org/10.3802/jgo.2019.30.e101

Ejemplares similares

Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC–IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2018)

Transdiaphragmatic resection of enlarged cardiophrenic lymph node during interval debulking surgery for advanced ovarian cancer
por: Addley, Susan, et al.
Publicado: (2021)

Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2020)

Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
por: Tozzi, Roberto, et al.
Publicado: (2019)

Primary diaphragmatic closure following diaphragmatic resection and cardiophrenic lymph node dissection during interval debulking surgery for advanced ovarian malignancy
por: Addley, Susan, et al.
Publicado: (2021)

Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team
por: Tozzi, Roberto, et al.
Publicado: (2021)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Laparoscopic resection of single site pelvic side wall recurrence 6 years after stage IIIc high grade serous primary peritoneal cancer
por: Addley, Susan, et al.
Publicado: (2021)

Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer
por: Derlatka, Pawel, et al.
Publicado: (2016)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

Pyometra presenting in conjunction with bowel cancer in a post-menopausal women: a case report
por: Soleymani majd, Hooman, et al.
Publicado: (2008)

The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients
por: Ye, Shuang, et al.
Publicado: (2022)

Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer
por: Zhou, Mingyi, et al.
Publicado: (2020)

Safety and feasibility of robotic surgery in selected ovarian cancer patients undergoing interval debulking surgery
por: Iavazzo, Christos, et al.
Publicado: (2020)

Misleading menorrhagia in a peri-menopausal woman with underlying bowel cancer: a case report
por: Soleymani majd, Hooman, et al.
Publicado: (2008)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma
por: Chambers, Laura M., et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients
por: Iwase, Haruko, et al.
Publicado: (2015)

The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high‐grade serous carcinoma
por: Kojima, Naoki, et al.
Publicado: (2019)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
por: Yoneoka, Yutaka, et al.
Publicado: (2019)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
por: He, Minjun, et al.
Publicado: (2021)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

Psychiatric morbidity after surgery for inflammatory bowel disease: A systematic review
por: Zangenberg, Marie Strøm, et al.
Publicado: (2017)

Does Endometriosis Hinder Successful Ovarian Debulking Surgery?
por: Sananpanichkul, Panya, et al.
Publicado: (2018)

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
por: McNamara, Blair, et al.
Publicado: (2021)

The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery
por: Zeng, Jing, et al.
Publicado: (2017)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2021)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
por: Lee, Yong Jae, et al.
Publicado: (2022)

Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer
por: Morton, Molly, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8tv4i36dlbrrivjc2jcrq4rh7m